interestingly COAST reports ph3 first in early Q2 2025 which is trial with eyelea - eyelea has $6B+ in sales and from memory OPT p2b in comparison to eyelea was better result than against lucentis (which only does about $1.5B of sales p.a)
So all in all - it’s the first trial result which will make or break this company
Ann: Security Class Reinstatement to Quotation- OPTOB, page-18
-
- There are more pages in this discussion • 307 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
80.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $991.0M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2519 | 83.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 76.5¢ | 1533 | 1 |
View Market Depth
| Last trade - 10.04am 05/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |
Day chart unavailable